AIM ImmunoTech Share Price Today

AIM ImmunoTech Q3 loss widens to $(0.21), sales drop 15.38%

AIM ImmunoTech posted a Q3 loss of $(0.21) per share, missing estimates by 61.54%. Sales declined 15.38% YoY to $22.000 thousand from $26.000 thousand. Loss per share improved from $(1.57) in the prior year period to $(0.21).

AIM ImmunoTech highlights Ampligen role in pancreatic cancer therapy

AIM ImmunoTech released an investor presentation on combining Ampligen with RAS-targeted therapies like daraxonrasib. Phase 3 data for daraxonrasib showed median overall survival of 13.2 months vs 6.7 months for chemotherapy. Historical Ampligen data showed median overall survival of 19.7 months vs 12.5 months in historical controls. Phase 2 DURIPANC topline results are expected in Q1 2027, with additional analyses in Q3 2027.

AIM ImmunoTech secures Long COVID patents in Europe and UK through 2041

AIM ImmunoTech secured three forms of patent protection for Ampligen in treating Long COVID across Europe and the UK. The intellectual property coverage extends through June 2041 after no opposition was filed during the review period. The patents cover specific dosing regimens and delivery methods including intranasal, intravenous, and inhalation administration. This follows a recent U.S. patent win for Ampligen in combination with pembrolizumab for cancer treatment. Clinical data shows over 1,200 patients enrolled and more than 100,000 doses administered with no drug-related deaths.

AIM ImmunoTech secures US patent for Ampligen combo therapy through 2039

AIM ImmunoTech secured a US patent for Ampligen combined with pembrolizumab. The patent covers cancer treatment methods using the drug combination. Expiration date is set for December 20, 2039. Coverage includes broad claims and specific cancer types like pancreatic and lung cancer. Existing IP portfolio includes patents in US, Netherlands, and Japan.

AIM ImmunoTech CEO urges proactive biodefense stockpiling in new article

AIM ImmunoTech CEO Thomas Equels published an article in Breaking Defense calling for proactive biodefense strategies. The piece highlights preclinical data where Ampligen showed 100% survival in Ebola-infected mice compared to 100% mortality in controls. Equels urges integrating such countermeasures into military force protection planning to address biological threats before they create operational emergencies.

AIM ImmunoTech Q2 loss widens to $3.8M, EPS misses estimates

AIM ImmunoTech's Q2 results show a widened net loss to $3.8 million and an EPS miss against consensus, though per-share losses improved significantly YoY. Revenue ticked up slightly to $26.000 thousand. Strong cash position supports ongoing clinical trials.